Oculis Reports Strong Cash Position and Advances Multiple Drug Candidates into Registrational Trials

summarizeSummary

Oculis Holding AG's annual report for 2025 reveals a significantly strengthened cash position of CHF 213.0 million and substantial progress across its clinical pipeline, with key drug candidates advancing into pivotal Phase 2/3 and registrational trials.

check_boxKey Events

• Strong Cash Position

  The company reported CHF 213.0 million in cash, cash equivalents, and short-term financial assets as of December 31, 2025, which is believed to be sufficient to fund operations for at least the next twelve months.

• Successful Capital Raises

  Oculis completed two underwritten offerings in February and November 2025, raising gross proceeds of $100.0 million (CHF 90.2 million) and $110.0 million (CHF 88.7 million) respectively.

• Pipeline Advancement into Registrational Trials

  OCS-01 is in two global pivotal Phase 3 trials for Diabetic Macular Edema (DME) with topline results expected in Q2 2026. Licaminlimab initiated the PREDICT-1 registrational Phase 2/3 trial for Dry Eye Disease (DED) in Q4 2025, with topline results anticipated in Q4 2026. Privosegtor advanced into the PIONEER registrational program for Optic Neuritis (ON) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), with trials initiating in Q4 2025 and H1/mid-2026.

• ATM Offering Program Terminated

  The $100.0 million At-The-Market (ATM) offering program, established in May 2024, was suspended and terminated in October 2025 without any sales, removing potential future dilution from this program.

auto_awesomeAnalysis

Oculis Holding AG's annual report for 2025 highlights a significantly improved financial position and substantial progress across its clinical pipeline. The company successfully raised significant capital through two underwritten offerings in 2025, contributing to a robust cash balance that is expected to fund operations for at least the next twelve months. Critically, Oculis has advanced multiple key drug candidates, OCS-01, Licaminlimab, and Privosegtor, into pivotal Phase 2/3 and registrational trials, with topline results anticipated in 2026. The termination of the ATM program without any sales also removes a potential source of future dilution. These developments are crucial for a clinical-stage biopharmaceutical company, signaling continued progress and financial stability.